Differences in the brain penetration of the anticholinergic drugs trospium chloride and oxybutynin

UroToday International Journal

Volumn 3, Issue 1, 2010, Pages

  Geyer, Joachim ^a   Gavrilova, Olga ^a   Schwantes, Ulrich ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Dr R Pfleger GmbH   (Germany)

Author keywords

Blood brain barrier; Multidrug resistance gene 1 (mdr1); Oxybutynin; P glycoprotein; Transport; Trospium chloride

Indexed keywords

EID: 76449117101     PISSN: None     EISSN: 19394810     Source Type: Journal    
DOI: 10.3834/uij.1944-5784.2010.02.12     Document Type: Article

References (20)

1. Andersson KE. Treatment of the overactive bladder syndrome and detrusor overactivity with antimuscarinic drugs. Continence. 2005;1(1):1-8.
2. Scheife R, Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther. 2005;27(2):144-153.
3. Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract. 2008;62(11):1792-1800.
4. Staskin DR, MacDiarmid SA. Using anticholinergics to treat overactive bladder: the issue of treatment tolerability. Am J Med. 2006;119(3 Suppl 1):9-15.
5. Wiedemann A, Schwantes PA. Antimuscarinic drugs for the treatment of overactive bladder: are they really all the same? A comparative review of data pertaining to pharmacological and physiological aspects. Eur J Ger. 2007;9:S29-S42.
6. Doroshyenko O, Jetter A, Odenthal KP, Fuhr U. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet. 2005;44(7):701-720.
7. Geyer J, Gavrilova O, Petzinger E. The role of P-glycoprotein in limiting brain penetration of the peripherally acting anticholinergic overactive bladder drug trospium chloride. Drug Metab Dispos. 2009;37(7):1371-1374.
8. Kay GG, Abou-Donia MB, Messer WS Jr, Murohy DG, Tsao JW, Ouslander JG. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc. 2005;53(12):2195-2201.
9. Diefenbach K, Donath F, Maurer A, et al. Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. Clin Drug Investig. 2003;23(6):395-404.
10. Diefenbach K, Arold G, Wollny A, Schwantes U, Haselmann J, Roots I. Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged ≥ 50 years. BJU Int. 2005;95(3):346-349.
11. Pietzko A, Dimpfel W, Schwantes U, Topfmeier P. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol. 1994;47(4):337-343.
12. Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol. 2001;41(6):636-644.
13. Shah GN, Mooradian AD. Age-related changes in the blood-brain barrier. Exp Gerontol. 1997;32(4-5):501-519.
14. Westergaard E, van Deurs B, Brondsted HE. Increased vesicular transfer of horseradish peroxidase across cerebral endothelium, evoked by acute hypertension. Acta Neuropathol. 1977;37(2):141-152.
15. Sage JI, Van Uitert RL, Duffy TE. Early changes in blood brain barrier permeability to small molecules after transient cerebral ischemia. Stroke. 1984;15(1):46-50.
16. Starr JM, Wardlaw J, Ferguson K, MacLullich A, Deary IJ, Marshall I. Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J Neurol Neurosurg Psychiatry. 2003;74(1):70-76.
17. Poduslo JF, Curran GL, Wengenack TM, Malester B, Duff K. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2001;8(4):555-567.
18. Skerjanec A, Devineni D. Affinity of darifenacin for the P-glycoprotein efflux pump: a mechanism contributing to the CNS sparing profile? Abstract C026, presented at the British Pharmacological Society Meeting. Newcastle, UK, December 14-16, 2004.
19. EMEA. Toviaz: European Public Assessment Report, Scientific discussion; 2007. European Medicines Agency Web site. http://www.ema.europa.eu/humandocs/PDFs/EPAR/toviaz/H-723-en6.pdf. Accessed January 22, 2010.
20. Michel MC, Minematsu T, Hashimoto T, den Hoven WV, Swart PJ. In vitro studies on the potential of solifenacin for drug-drug interactions: plasma protein binding and MDR1 transport. Proceedings of the BPS Clinical Pharmacology Section 14-16. Br J Clin Pharmacol. 2004;59(5):647.